Faculty

Stephan A. Grupp, MD, PhD
Section Chief, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Program
Medical Director, Cell and Gene Therapy Laboratory
Children's Hospital of Philadelphia
Philadelphia, PA

About the presenter

Dr. Stephan A. Grupp is section chief of the cellular therapy and transplant section, director of the Cancer Immunotherapy Program, and medical director of the Cell and Gene Therapy Laboratory. He holds the Yetta Deitch Novotny Endowed Chair in pediatric oncology.

As an attending physician in the Cancer Center, Dr. Grupp takes on many roles at CHOP. He received an MD and PhD from the University of Cincinnati College of Medicine and completed residency and fellowships at Harvard Medical School, Boston Children’s Hospital, Dana Farber Cancer Institute and Brigham and Women’s Hospital, before coming to CHOP in 1996.

In one of his clinical roles, he works with patients with the most aggressive form of neuroblastoma, a difficult-to-treat childhood cancer that begins in the peripheral (non-brain) nerve tissue of infants and young children. He works alongside a world-class team of physicians and multidisciplinary specialists who are dedicated to treating this disease. The tandem-transplant approach that is now the standard of care across the country was developed by this group at CHOP. In addition, the neuroblastoma team at CHOP does studies of the patient’s genetics and the unique characteristics of their disease to offer a personalized treatment approach. The team also did the nationwide clinical trial establishing antibody-based immunotherapy as the new standard of care in neuroblastoma.

Planning Committee

Elizabeth Albert, MD
Clinical Activity Manager
OptumHealth Education
Eden Prairie, MN

Matthew Cooper, MD
President, UNOS Board of Directors;
Director, Kidney and Pancreas Transplantation
Medstar Georgetown Transplant Institute;
Professor of Surgery
Georgetown University School of Medicine
Washington, DC

Rebecca Gleason, RN, CCM
Activity Manager
OptumHealth Education
Eden Prairie, MN

Alan N. Langnas, DO, FACS
Professor of Surgery
Director, Center of Transplantation
Chief, Section of Transplantation,
Department of Surgery
University of Nebraska Medical Center;
Director of Liver Transplantation
Nebraska Medicine
Omaha, NE

C. Fred LeMaistre, MD
Senior Vice President
Senior Vice President, Market Operations
Physician-in-Chief, Hematology
Sarah Cannon
Nashville, TN

Tina Rydland, PharmD
President
ArdentCare Solutions
Denver, CO

Disclosures of relevant financial relationships

In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Dr. Grupp has indicated that he is a consultant for Novartis and Vertex, serves on the advisory board for Novartis and Vertex, and receives grant/research funding from Novartis and Vertex.

The activity planners have no financial relationships to disclose.